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Introduction
Chronic recurrent multifocal osteomyelitis (CRMO) is
the most common autoinflammatory osteopathy. CRMO
is characterized by non-bacterial osteomyelitis and pri-
marily affects children and adolescents. The disorder has
a relapsing and remitting course. While non-steroidal
anti-inflammatory drugs (NSAIDs) are used as first-line
treatment, glucocorticoids and disease-modifying anti-
rheumatic drugs have been reported to be effective in
some cases. In resistant cases, the effects of TNF-a inhi-
bitors or bisphosphonates were observed.
Objectives
To describe a cohort of CRMO patients and to charac-
terize treatment effects with focus on bisphosphonates
in a retrospective study of a case series.
Methods
Between 1995 and 2014 we diagnosed CRMO in 17
patients (14 females and 2 males). The mean age at diag-
nosis was 9.2 years. The time between symptom onset and
diagnosis of CRMO ranged from 3 to 72 months. We
found multilocal lesions involving the tibia, clavicle, femur,
vertebral bodies, pelvis and mandible. The average number
of lesions per patient was 3.8. The diagnosis of CRMO was
based on radiographic findings (X-ray, CT, MRI, scintigra-
phy) and biopsy. In the histopathology are typical cell infil-
trates – predominantly neutrophils in the early stages,
monocytes, macrophages, lymphocytes and plasma cells in
the later stages; and osteolyses with sclerosis and/or fibro-
sis in late CRMO phases. After confirming CRMO all
patients were treated with NSAID.
Results
NSAID was ineffective in 8 out of 17 patients who then
received a corticosteroid therapy. 4 of these patients
(3 girls and 1 boy) did not fully respond and were treated
with intravenous pamidronate. In 2 patients pamidronate
was added to MTX and/or Sulphasalzine (n=2) while the
other 2 patients were MTX/Sulphasalazine naive.
In MTX/Sulphasalazine naive patients, 1 reached com-
plete remission after a single dose and 1 after a double
dose in a 6 month regimen. In these patients no corticos-
teroids were needed after pamidronate therapy.
Two patients with previous MTX/Sulphasalazine treat-
ment, the dosing regimen at 6-month intervals was inade-
quate, requiring a dose increase to 3-month intervals. One
of these patients was treated with anti-TNF-a inhibitors
prior to pamidronate, but without sufficient effect. These
patients have improved only partially and required treat-
ment with corticosteroids. In both groups no adverse
effects were observed.
Conclusion
In accordance with published data, our experience con-
firms good effect of pamidronate therapy in patients with
resistant CRMO, however more severe cases with multiple
bone lesions and/or systemic symptoms (febrile, inflam-
matory skin disorders, weight loss or growth retardation)
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